HC Wainwright Issues Negative Outlook for NAMS Earnings

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) – Analysts at HC Wainwright decreased their Q3 2026 earnings per share estimates for shares of NewAmsterdam Pharma in a report issued on Thursday, August 6th. HC Wainwright analyst L. Egana-Gorrono now expects that the company will post earnings of ($0.62) per share for the quarter, down from their prior forecast of ($0.58). The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.81) per share. HC Wainwright also issued estimates for NewAmsterdam Pharma’s Q4 2026 earnings at ($0.28) EPS and FY2026 earnings at ($1.82) EPS.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.04). NewAmsterdam Pharma had a negative return on equity of 34.81% and a negative net margin of 3,644.21%.The firm had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $2.83 million.

Several other equities analysts have also commented on NAMS. BMO Capital Markets assumed coverage on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. They set an “outperform” rating and a $58.00 price objective for the company. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Jefferies Financial Group restated a “buy” rating and set a $45.00 target price on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Friday, July 17th. Finally, Royal Bank Of Canada dropped their price target on NewAmsterdam Pharma from $51.00 to $50.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $49.33.

NewAmsterdam Pharma Stock Performance

Shares of NAMS opened at $27.98 on Monday. The company’s fifty day moving average is $31.30 and its 200 day moving average is $32.47. NewAmsterdam Pharma has a fifty-two week low of $23.05 and a fifty-two week high of $42.21. The stock has a market capitalization of $3.27 billion, a PE ratio of -12.95 and a beta of 0.10.

Institutional Trading of NewAmsterdam Pharma

Several institutional investors and hedge funds have recently modified their holdings of the stock. Farther Finance Advisors LLC grew its stake in NewAmsterdam Pharma by 4,425.0% in the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after purchasing an additional 708 shares in the last quarter. Wells Fargo & Company MN raised its position in NewAmsterdam Pharma by 50.0% during the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after purchasing an additional 300 shares in the last quarter. KBC Group NV bought a new stake in NewAmsterdam Pharma during the 1st quarter valued at $37,000. Navalign LLC bought a new stake in NewAmsterdam Pharma during the 4th quarter valued at $46,000. Finally, AdvisorNet Financial Inc purchased a new stake in shares of NewAmsterdam Pharma in the 1st quarter worth $82,000. Institutional investors own 89.89% of the company’s stock.

Insider Buying and Selling

In related news, CAO Louise Frederika Kooij sold 105,000 shares of NewAmsterdam Pharma stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $30.34, for a total transaction of $3,185,700.00. Following the completion of the sale, the chief accounting officer owned 24,353 shares in the company, valued at $738,870.02. This trade represents a 81.17% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last quarter, insiders have sold 210,000 shares of company stock valued at $6,713,550. Company insiders own 12.74% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.